Guide
Weight Regain After Stopping Tirzepatide: What the Withdrawal Data Shows
Published withdrawal data across GLP-1s is consistent: a substantial share of lost weight returns after discontinuation, and the regain begins within months. That is the
Published withdrawal data across GLP-1s is consistent: a substantial share of lost weight returns after discontinuation, and the regain begins within months. That is the strongest argument for treating annual maintenance cost as the real price rather than a first-year figure.
What does the evidence actually show?
| Scenario | What the data shows | Source type |
|---|---|---|
| Continued treatment | Weight maintained or loss continues | Trial extension data |
| Discontinued | Substantial regain within about a year | Withdrawal arms |
| Discontinued with lifestyle support | Regain slowed, not prevented | Consistent finding |
If stopping returns the weight, then treatment is indefinite, and the number that matters is what a maintenance year costs — not an introductory rate, and not a first-year total.
A programme advertising $129 that escalates to $299 is not a cheaper programme. It is a more expensive one with a cheaper first month, and the withdrawal data is what turns that from a quibble into the decision.
None of this means stopping is wrong. It means it is a clinical decision with a predictable consequence, and worth planning rather than discovering.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does treatment cost while this is true?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Do you regain weight after stopping tirzepatide?
Published withdrawal data across GLP-1s consistently shows a substantial share of lost weight returns, beginning within months of discontinuation.
Does lifestyle support prevent regain?
The data suggests it slows regain rather than preventing it.
What does that mean for cost?
It makes annual maintenance cost the figure that matters, not an introductory rate or a first-year total, because treatment is effectively indefinite.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- What Happens After You Stop Tirzepatide?Journal
- Monthly vs Prepaid GLP-1 ProgramsComparisons
- Best Month-to-Month Tirzepatide ProgramsPillar / Money
- Annual GLP-1 Cost CalculatorTools
- Tirzepatide Annual Cost Calculator and ComparisonPillar / Money
- SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
- NexLife vs FoundComparisons
Related coverage
GLP-1 Tirzepatide Rank. “Weight Regain After Stopping Tirzepatide: What the Withdrawal Data Shows.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-weight-regain-after-stopping-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.